ResearcherMonash UniversityActive in the last 2 years
Adrian M. Fox
Matched on ORCID iD 0000-0002-1143-9129; OpenAlex author ID A5030494687, A5043519707. Sources: ClinicalTrials.gov.
Their work
- Papers
- 5
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2019: 1 paper · 2020: none · 2021: 1 trial · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper
Papers 5
- A retrospective analysis of Selective Internal Radiation Therapy (SIRT) and chemotherapy for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1186/s12885-026-16113-z↗
- Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysis. Co-author DOI 10.1016/j.esmorw.2023.100022↗
- Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data. Co-author DOI 10.1038/s41416-024-02619-5↗
- Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. Co-author DOI 10.1111/ajco.13807↗
- Body Composition Adjusted Dosing of Gemcitabine-Nab-Paclitaxel in Pancreatic Cancer Does Not Predict Toxicity Compared to Body Surface Area Dosing. Co-author DOI 10.1080/01635581.2018.1542011↗
Trials 1
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Benjamin N. J. Thomson · 3 shared papers, 2023–2024 · strength 0.45
- Paper Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data. DOI 10.1038/s41416-024-02619-5↗
- Paper Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, mu… DOI 10.1016/j.esmorw.2023.100022↗
- Paper Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australa… DOI 10.1111/ajco.13807↗
- Peter Gibbs · 3 shared papers, 2023–2024 · strength 0.45
- Paper Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data. DOI 10.1038/s41416-024-02619-5↗
- Paper Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, mu… DOI 10.1016/j.esmorw.2023.100022↗
- Paper Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australa… DOI 10.1111/ajco.13807↗
- Mehrdad Nikfarjam · 3 shared papers, 2023–2024 · strength 0.45
- Paper Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data. DOI 10.1038/s41416-024-02619-5↗
- Paper Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, mu… DOI 10.1016/j.esmorw.2023.100022↗
- Paper Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australa… DOI 10.1111/ajco.13807↗
- Belinda Lee · 3 shared papers, 2023–2024 · strength 0.45
- Paper Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data. DOI 10.1038/s41416-024-02619-5↗
- Paper Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, mu… DOI 10.1016/j.esmorw.2023.100022↗
- Paper Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australa… DOI 10.1111/ajco.13807↗
- Prasad D. Cooray · 2 shared papers, 2023–2026 · strength 0.41
- Paper A retrospective analysis of Selective Internal Radiation Therapy (SIRT) and chemotherapy for metastatic pancreatic aden… DOI 10.1186/s12885-026-16113-z↗
- Paper Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australa… DOI 10.1111/ajco.13807↗
- Benjamin P. T. Loveday · 2 shared papers, 2024 · strength 0.32
- Yat Hang To · 2 shared papers, 2024 · strength 0.32
- Adnan M. Nagrial · 2 shared papers, 2023–2024 · strength 0.29
- Paper Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, mu… DOI 10.1016/j.esmorw.2023.100022↗
- Paper Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australa… DOI 10.1111/ajco.13807↗
- Matthew Burge · 2 shared papers, 2023–2024 · strength 0.29
- Paper Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, mu… DOI 10.1016/j.esmorw.2023.100022↗
- Paper Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australa… DOI 10.1111/ajco.13807↗
- Sue S. Thang · 1 shared paper, 2026 · strength 0.28
- Vijayaragavan Muralidharan · 1 shared paper, 2026 · strength 0.28
- Ashleigh R. Poh · 1 shared paper, 2026 · strength 0.28
- Shehara Ramyalini Mendis · 1 shared paper, 2024 · strength 0.16
- Sam Banks · 1 shared paper, 2024 · strength 0.15
- Hyun Soo Ko · 1 shared paper, 2024 · strength 0.15
- Niall Christopher Tebbutt · 1 shared paper, 2023 · strength 0.14
- Marion Harris · 1 shared paper, 2023 · strength 0.14
- Imogen Walpole · 1 shared paper, 2023 · strength 0.14
- Gregory Thomas Moore · 1 shared paper, 2019 · strength 0.11
- Julia Freckelton · 1 shared paper, 2019 · strength 0.11
- Margaret Lee · 1 shared paper, 2019 · strength 0.11
- Daniel Gerald Croagh · 1 shared paper, 2019 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.